Is Matrixyl Safe? Safety Profile 2026 — PeptidePrices

Q: Is Matrixyl safe?

Matrixyl has a safety rating of 9/10 in our methodology — good. Thousands of skincare products; extensive safety data; topical only; extremely well-tolerated

Q: Is Matrixyl FDA approved?

FDA status: Cosmetic use (topical). PeptidePrices does not sell or recommend any compound for human use; this information is for research-context only.

Q: Where can I find verified Matrixyl?

PeptidePrices tracks live prices and COA verification status across 30+ vendors. See our cheapest Matrixyl listings for prices ranked by COA tier and $/mg.

Safety Profile

Matrixyl

Updated today

Cosmetic Peptide

9/10Good

How we score compound safety →

Primary use: Skin / collagen research

Regulatory Status

Cosmetic use (topical)

Safety Summary

Thousands of skincare products
extensive safety data
topical only
extremely well-tolerated

Matrixyl sits in our well-studied tier (9/10). The safety dataset is robust, mechanisms are characterized, and side-effect patterns are predictable. Researchers working with this compound should still verify vendor COA quality — a clean safety profile means nothing if the vial contains the wrong compound or is under-dosed. Researchers often consider GHK-Cu and Snap-8 as alternatives in the same category — see the related-compounds section below for safety comparisons.

Molecular Profile

TypePalmitoylated pentapeptide

Molecular Weight802.05 g/mol

Amino Acids5 (palmitoylated)

CAS Number214047-00-4

SequencePal-Lys-Thr-Thr-Lys-Ser

Storage

Lyophilized−20°C, long-term stable

Reconstituted2–8°C, within 30 days

Protect from light
Avoid repeated freeze-thaw
Topical-research compound

Related Compounds

Methodology

How we rate peptide safety

Every compound in our index gets a 1–10 safety score based on four weighted factors. The score reflects known research-use risk — not medical advice.

40% — Clinical evidence. Volume of peer-reviewed trials, sample sizes, duration, and consistency of outcomes. FDA-approved compounds anchor the top end (8–10); preclinical-only compounds cap at 6.
30% — Adverse-event profile. Severity and frequency of reported side effects, including GI events, cardiovascular signals, hypoglycemia, and long-term organ effects.
20% — Regulatory status. FDA approval, EMA approval, or status in active clinical trials. Compounds under safety warnings are penalized.
10% — Community-reported outcomes. Reddit, forum, and published case-report signal beyond formal trials. Used as a late-stage tiebreaker, not a leading factor.

9–10Well-studied, FDA-approvedLarge-trial evidence, established long-term safety. Examples: semaglutide, tesamorelin at approved doses.

7–8Mostly safe, some caveatsPhase 2/3 evidence or long community track record with known manageable side effects. Routine monitoring recommended.

5–6Mixed dataLimited clinical trials, mostly community/preclinical data. Real but uncertain risk profile.

3–4Caution advisedKnown side-effect patterns, thin safety data, or compounds under active regulatory scrutiny.

1–2Significant risk signalsDocumented serious adverse events (cardiovascular, hepatotoxicity, contamination) or withdrawn regulatory status.

Related compounds

Other compounds researchers compare with Matrixyl

Full Matrixyl profile Cheapest Matrixyl deals

Safety ratings are derived from published clinical data, FDA approval status, and community-reported outcomes. They are not medical advice. Always consult a healthcare professional before using any research compound.